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Live vaccinia virus (VV) vaccination has been highly successful in eradicating smallpox. However, the
mechanisms of immunity involved in mediating this protective effect are still poorly understood, and the roles
of CD8 T-cell responses in primary and secondary VV infections are not clearly identified. By applying the
concept of molecular mimicry to identify potential CD8 T-cell epitopes that stimulate cross-reactive T cells
specific to lymphocytic choriomeningitis virus (LCMV) and VV, we identified after screening only 115 peptides
two VV-specific immunogenic epitopes that mediated protective immunity against VV. An immunodominant
epitope, VV-e7r130, did not generate cross-reactive T-cell responses to LCMV, and a subdominant epitope,
VV-a11r198, did generate cross-reactive responses to LCMV. Infection with VV induced strong epitope-specific
responses which were stable into long-term memory and peaked at the time virus was cleared, consistent with
CD8 T cells assisting in the control of VV. Two different approaches, direct adoptive transfer of VV-e7r-specific
CD8 T cells and prior immunization with a VV-e7r-expressing ubiquitinated minigene, demonstrated that
memory CD8 T cells alone could play a significant role in protective immunity against VV. These studies
suggest that exploiting cross-reactive responses between viruses may be a useful tool to complement existing
technology in predicting immunogenic epitopes to large viruses, such as VV, leading to a better understanding
of the role CD8 T cells play during these viral infections.
Prior immunity to unrelated pathogens can sometimes sig-
nificantly alter the course and outcome of unrelated virus in-
fections in mice, and this can be either beneficial or detrimen-
tal to the host (43, 47, 57, 58). For instance, immunity to
lymphocytic choriomeningitis virus (LCMV) can protect mice
from a lethal dose of vaccinia virus (VV), and these mice may
show altered T-cell-mediated immunopathology resulting in
bronchiolitis obliterans or acute fatty necrosis (8, 46). Heter-
ologous immunity may play a role in the variability observed in
human disease outcome, from subclinical to lethal, in individ-
uals with the same infection or vaccination.
In 1980, the World Health Organization announced that
smallpox (variola) had been eradicated by vaccination with
VV; however, smallpox is now considered a potential bioter-
rorist agent (23). The use of modified VV for mixed-modality
vaccines to boost immune responses that have been primed
with other agents, such as DNA vaccines or adenovirus vectors
expressing viral epitopes, is now being advocated (1). Concerns
have arisen about the safety of VV as a vaccine. Adverse
events, such as fulminant disseminating vaccinia, have oc-
curred in immunodeficient individuals, while many significant
immunity-mediated conditions, such as severe dermatological
diseases (erythema multiforme and erythema nodosum), ar-
thritis, pericarditis, myocarditis, and encephalitis, have oc-
curred in healthy individuals following VV vaccination against
smallpox (7, 19, 32, 36). Heterologous immunity may be play-
ing a role in mediating some of this immunopathology, espe-
cially in adults, who would have large complex memory pools
following a lifetime of infections. Thus, studies on heterolo-
gous immunity in the mouse model may be highly relevant to
human disease, since vaccination with VV has again become
prevalent.
Despite the great success of this live vaccine, the precise
mechanisms of immunity associated with protection are still
poorly understood. There has been evidence for both cellular
immunity and humoral immunity playing a role. The level of
serum-neutralizing antibody has been correlated with protec-
tive immunity. However, the observation that T-cell-deficient
individuals had serious and at times fatal infections following
VV immunization while agammaglobulinemic children did not
suffer such complications suggests that cellular immunity plays
an important role in clearing the infection (18, 36, 37, 39). It
has been shown that both arms of the immune response are
complementary in mediating protection against ectromelia vi-
rus (mouse pox), a poxvirus closely related to VV. CD8 T-cell
responses were essential for clearing ectromelia virus early in a
primary infection, while antibodies were important later in
ectromelia virus infection (15, 25). The importance of CD8
T-cell responses during both primary and secondary VV infec-
tions is less clear. Previous studies using VV infection of mice
have had equivocal results concerning the role of CD8 T cells,
although most studies are consistent with CD8 T cells playing
at least a supportive role in protective immunity (3, 13, 49, 50,
59). Ongoing research is focusing on developing new and safer
vaccines (14). In order to achieve this, it is important to have
a better understanding of the impact of T-cell responses on VV
infection, including their roles both in protective immunity and
in mediating immunopathology.
VV infection of LCMV-immune mice leads to the activation
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of T cells specific to many different LCMV epitopes. LCMV-
NP205-specific CD8 T cells expanded most frequently, presum-
ably due to cross-reactivity with VV (27). Interestingly,
LCMV-NP205-specific CD8 T-cell responses are also cross-
reactive with a similar epitope encoded by Pichinde virus (PV),
PV-NP205. Six of eight amino acids are common between the
LCMV and PV epitopes in sites important for interaction with
the T-cell receptor (TCR) (5). CD8 T-cell responses may be
cross-reactive with different antigens (5, 10, 27, 56, 58), and a
common model for cross-reactivity is molecular mimicry, in
which two peptides have sequence similarity at the sites of
TCR recognition (16, 17). We used the concept of molecular
mimicry as a premise to identify potential cross-reactive
epitopes between LCMV and VV. This has led to the identi-
fication of two VV-specific CD8 T-cell epitopes in mice. Both
of these epitopes induced highly effective VV-specific acute
and long-term memory responses. One of these epitopes, VV-
a11r198, activated cross-reactive LCMV-specific memory T
cells, but its discovery unexpectedly led to the identification of
a matrix of cross-reactive responses involving five different
epitopes and three different viruses (M. Cornberg, S. C. Clute,
F. M. Saccoccio, S. K. Kim, Y. N. Naumov, M. A. Brehm,
R. M. Welsh, and L. K. Selin, submitted for publication).
Interestingly, the other epitope, VV-e7r130, which is described
in more detail here, did not appear to activate cross-reactive
LCMV-specific memory T-cell responses, even though it was
identified by using the concept of molecular mimicry. We here
demonstrate that, by our use of VV-e7r130-ubiquitinated mini-
gene immunization or adoptive transfer of VV-e7r130-specific
CD8 T-cell lines, memory CD8 T cells can play a significant
role in mediating protective immunity to VV during a second-
ary infection.
MATERIALS AND METHODS
Mice. C57BL/6 (B6; H-2b) male mice were purchased from The Jackson
Laboratory (Bar Harbor, ME), and B6.SJL-ptprca (LY5.1) congenic male mice
were purchased from Taconic Farms (Germantown, NY). Mice were used at 2 to
8 months of age. All mice were maintained under specific-pathogen-free condi-
tions in the University of Massachusetts Medical School, Department of Animal
Medicine.
Cell lines. ATCC Vero cells, used in plaque assays, were cultured in minimum
essential medium (MEM; Invitrogen, Carlsbad, CA). MC57G cells, which are an
H-2b-expressing methylcholanthrene-induced fibroblast cell line from B6 mice,
were used as stimulators in intracellular cytokine staining (ICS) assays or as
targets for 51Cr release cytotoxicity assays and were maintained in MEM.
MC57G cells were infected with VV at a multiplicity of infection of 10 PFU/cell
and incubated for 1 h at 37°C. The TAP-2-deficient B6-derived T-lymphoma cell
line, RMA-S, kindly provided by Hans-Gustaf Ljunggren (Karolinska Institute,
Stockholm, Sweden), was grown in RPMI. RMA-S cells were pulsed with 1 M
peptide for 1 h at 37°C and were then used as targets in 51Cr release cytotoxicity
assays. As stimulators for CD8 T-cell lines, RMA-S cells were incubated with 1
M peptide for 1 h at 37°C and then irradiated (3,000 rads). All cell lines were
supplemented with 100 U/ml penicillin G, 100 g/ml streptomycin sulfate, 2 mM
L-glutamine, 10 mM HEPES, and 10% heat-inactivated (56°C, 30 min) fetal
bovine serum (FBS; Sigma Chemical Co., St. Louis, MO).
Viruses. The Western Reserve (WR) strain of VV, a DNA virus in the or-
thopoxvirus family, was propagated in L929 cells (45). LCMV (Armstrong
strain), an RNA virus in the Old World arenavirus family, was propagated in
BHK-21 baby hamster kidney cells (45). The mouse adapted influenza virus
A/PR/8/34 (H1N1), an RNA virus in the orthomyxovirus family, was grown in
the allantoic fluid of 10-day-old embryonated chicken eggs (SPAFAS,
Preston, CT) (9).
Infection protocols. For virus infections, mice were infected intraperitoneally
(i.p.) with 5  104 PFU of LCMV or 106 PFU VV and methoxyflurane (Meto-
fane)-anesthetized mice were challenged intranasally with 70 PFU of influenza A
virus. To control for culture contaminants, VV stocks were purified through a
sucrose gradient and diluted in Hanks’ balanced salt solution (HBSS; Invitrogen,
Carlsbad, CA) and LCMV was diluted more than 40-fold in HBSS. Mice were
considered immune 6 weeks after infection or later. Control naı¨ve mice were
either left uninoculated or inoculated with tissue culture media or HBSS. The
control mice were always age matched to mice of the experimental group and
housed exactly the same under pathogen-free conditions.
Virus titration. VV titers in each of the organs (fat pads, testes, spleens, lungs,
kidneys, brains, salivary glands, hearts, and livers) were determined by plaque
assays on ATCC Vero cells with the use of a 10% homogenate of tissue taken
from individual mice, as described elsewhere (46).
Identification and screening for potential cross-reactive VV epitopes. In order
to identify potential VV epitopes cross-reactive with the H-2Kb-restricted
LCMV-NP205 epitope (YTVKYPNL) (55), we searched the VV sequence for
8-mers which maintained the H-2Kb binding motif (i.e., Y or F in the fifth
position and L or M in the eighth position) and had 30% or more sequence
similarity to LCMV-NP205 by using the DNA/RNA and protein analysis software
DNASIS (Hitachi Software Engineering Company, Ltd.). This identified 115
potential peptides, which were synthesized by Chiron Mimitopes (San Diego,
CA) and then screened in intracellular gamma interferon (IFN-) assays using
splenocytes or blood samples from day 8 LCMV- and day 6 VV-infected mice.
Although the initial screening was done with mimotope peptides, all experiments
shown here used synthetic peptides generated by Biosource International (Ca-
marillo, CA), which were purified with reverse-phase high-pressure liquid chro-
matography to 90% purity. Final products were analyzed by mass spectroscopy.
Two H-2Kb-restricted epitopes were identified, one in the VV protein e7r,
positions 130 to 137 (STLNFNNL), and the second in the VV protein a11r,
positions 198 to 205 (AIVNYANL). For controls, the influenza virus epitope
NP366Db (ASNENMETM) (52) and the LCMV epitope NP396Db (FQPQNG
QFI) (20) were used.
Cell surface and tetramer staining by flow cytometry. Single cell suspensions
were prepared from splenocytes, peritoneal exudates (PECs), or peripheral
blood. Erythrocytes were lysed with 0.84% NH4Cl solution. Cell suspensions
were incubated in fluorescence-activated cell sorter buffer (phosphate-buffered
saline [PBS] containing 2% FBS and 0.2% sodium azide) with anti-mouse CD16/
CD32 (Fc-block, 2.4G2) to avoid nonspecific antibody binding. Cells were
washed, and surface staining was performed in 96-well plates with fluorochrome-
labeled antibodies perdinin chlorophyll protein (PerCP)–anti-mouse CD8-alpha
(clone 53-6.7) and fluorescein isothiocyanate–anti-mouse CD44 (clone IM7). For
tetramer staining, cells were first incubated with streptavidin and Fc-block to
prevent nonspecific binding, washed, and then stained with phycoerythrin (PE)
and/or allophycocyanin (APC)-labeled tetramers for 60 min. After 40 min of
tetramer incubation, surface antibodies were added for 20 min. Thereafter, cells
were washed twice with fluorescence-activated cell sorter buffer and fixed in
Cytofix (BD Pharmingen, San Diego, CA). All staining was performed on ice.
Samples were analyzed with a Becton Dickinson FACSCalibur flow cytometer
(San Jose, CA) and FlowJo software (Tree Star, Inc., Ashland, OR). All surface
antibodies were purchased from BD Pharmingen, San Diego, CA. Major histo-
compatibility complex class I (MHC-I) peptide tetramers specific for VV-e7r130/
H-2Kb and VV-a11R198/H-2Kb were generated as described previously (11, 27).
ICS. Cells (106) were stimulated with medium, 5 M synthetic peptide, 5
g/ml anti-CD3 (145-2C11), or 105 VV-infected cells (MC57G). Stimulations
were performed for 5 h at 37°C in a total volume of 200 l RPMI medium
supplemented with 10% FBS, 10 U/ml of human recombinant interleukin-2
(IL-2), and 0.2 M of brefeldin A (GolgiPlugTM; BD Pharmingen). After
incubation, the surface staining was carried out as described above. Thereafter,
cells were washed twice, and then fixed and permeabilized (Cytofix/Cytoperm;
BD Pharmingen, San Diego, CA). Intracellular-cytokine-producing cells were
detected with PE-labeled anti-mouse IFN- and APC-labeled anti-mouse tumor
necrosis factor alpha (TNF-) monoclonal antibodies. Immunoglobulin G iso-
type antibodies labeled with the same fluorochromes were used in the same
assay. Antibodies were purchased from BD Pharmingen, San Diego, CA. The
samples were analyzed as described above.
Cytotoxicity assays. Standard in vitro chromium (51Cr) release assays were
performed to measure antiviral cytotoxic-T-lymphocyte (CTL) activity as de-
scribed previously (45). The in vivo cytotoxicity assay was performed according to
recently published techniques (2, 28), with splenocytes from B6 or congenic
LY5.1 mice used as target cells. After the lysis of red blood cells, splenocytes
were divided into two or four populations. One population was pulsed with 1 M
ovalbumin amino acids 257 to 264 (SIINFEKL) as a control, and other popula-
tions were pulsed with 1 M of the indicated VV peptides for 60 min at 37°C.
Each population was labeled with a different concentration (2 M or 0.4 M for
the two-population experiment; 2 M, 0.67 M, 0.33 M, or 0.11 M for the
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four-population experiment) of carboxyfluorescein diacetate-succinimidyl ester
(CFSE; Molecular Probes, Eugene, OR). After CFSE labeling, equal amounts of
cells were mixed together, washed, and resuspended in PBS. A total of 2  107
cells were injected intravenously into each recipient mouse. Specific in vivo
cytotoxicity was determined by harvesting splenocytes from recipient mice 16 h
after intravenous cell transfer. CFSE-labeled target populations were quantified
by flow cytometry. When splenocytes from LY5.1 congenic mice were used as
target cells, splenocytes from recipients were costained with a PE-conjugated
LY5.1-specific monoclonal antibody (CD45.1, clone A20; BD Pharmingen). By
gating on LY5.1-specific cells, it was possible to include four target populations
per sample. Uninfected, LCMV- and VV-infected C57BL/6 mice were used as
recipients. The amount of specific in vivo killing was calculated, as described
elsewhere (2), as follows:
100  {[(% peptide pulsed in infected/% unpulsed in infected)/(% peptide
pulsed in uninfected/% unpulsed in uninfected)]  100}.
In vitro expansion of antigen-specific CTLs. Splenocytes (107) from VV- or
LCMV-immune mice were cocultured with peptide-pulsed RMA-S cells (106) in
RPMI supplemented with 100 U/ml penicillin G, 100 g/ml streptomycin sulfate,
2 mM L-glutamine, 10 mM HEPES, 1 mM sodium pyruvate, 0.1 mM MEM-
nonessential amino acids, 0.05 mM -mercaptoethanol, and 10% FBS for 4 to 5
days at 37°C at 5% CO2. The IL-2 culture supplement BD T-Stim (BD Bio-
sciences, San Diego, CA) was added after 4 to 5 days of culture. Peptide stim-
ulation was repeated every 4 to 5 days. After 20 to 25 days of stimulation (four
or five stimulations), T-cell lines were analyzed.
Adoptive transfer of antigen-specific T cells into mice. T-cell lines were rested
without peptide stimulation for 7 days. Thereafter, live cells were separated with
Lympholyte-M (Cedarlane, Hornby, Canada). T cells were suspended in HBSS
at 107 cells/ml and incubated with 2 M CFSE for 15 min at 37°C. After
incubation, cells were washed twice with HBSS, and 106 cells were injected i.p.
into recipient mice. Mice were infected with 106 PFU VV i.p. on the same day.
Three to four days after infection, mice were sacrificed. Fat pads and/or testes
were analyzed for VV titers. PECs were analyzed for immune responses and
division of transferred T cells. Surface staining was performed as described
above, with fluorochrome-labeled antibodies perdinin chlorophyll protein–anti-
mouse CD45.2 (LY5.2, clone 104) and APC–anti-mouse CD8-alpha (clone 53-
6.7). Transferred donor cells were identified as positive for CD45.2 and CD8
when congeneic mice were used.
VV-e7r130-specific minigene DNA immunization. Ubiquitinated DNA vaccine
constructs expressing VV-e7r130 epitope were prepared as described elsewhere
(42). The genes for VV-e7r130 were cloned into the F3Ub expression vector
kindly provided by Lindsay Whitton (Scripps Institute, San Diego, CA). Clean
lipopolysaccharide-free plasmid DNA was produced by using plasmid Giga kit
(QIAGEN, Valencia, CA), according to manufacturer’s protocol. For immuni-
zation, the quadriceps muscles of B6 mice were injected with 100 g (50 g for
each muscle) of DNA construct formulated in sterile 0.9% NaCl. The control
mice were immunized with 100 g of F3Ub vector or LCMV-NP396-specific
minigene or were not immunized. Mice received three DNA immunizations (100
g each) separated by two weeks. Two weeks after the last immunization, mice
were infected with 106 PFU VV. Six days after VV infection, mice were sacri-
ficed. Splenocytes and PECs were analyzed by intracellular cytokine staining and
by in vitro 51Cr release assays. Fat pads were evaluated for virus titers by plaque
assays.
Statistical analysis. Descriptive statistics are expressed as mean values 
standard errors of the mean. Comparisons between groups were performed with
the Student t test (two tailed).
RESULTS
Cross-reactive peptide motif identifies H2-Kb-restricted VV-
specific CD8 T-cell epitopes. Defining VV-specific epitopes has
not been a priority until recent times, as smallpox had been
essentially eradicated. Identifying epitopes for VV can be a
daunting task, as VV is a very large DNA virus of the or-
thopoxvirus family and expresses over 200 proteins, with the
potential for thousands of CD8 T-cell epitopes (21). Human
and mouse VV-specific CD8 T-cell epitopes have only very
recently been identified (13, 33, 35, 51, 53). We took a unique
approach to identifying VV-specific epitopes because our pre-
vious work had revealed selective expansion of LCMV
epitope-specific T cells during VV infection, consistent with
potential cross-reactive T-cell responses (8, 26, 27). In order to
further examine cross-reactive responses between VV and
LCMV, we had to define VV-specific epitopes. Since CD8 T
cells specific for the LCMV-NP205 peptide often expanded
during VV infection of LCMV-immune mice, this peptide was
used as a template peptide sequence to identify potential cross-
reactive epitopes with sequence similarity. By use of a general
DNA/RNA and protein analysis software (DNASIS) and the
criteria that the epitope should have an H-2Kb binding motif
and greater than 30% sequence similarity to LCMV-NP205
(YTVKYPNL), 115 8-mer peptides were identified in the VV
genome. By screening these peptides by use of an intracellular
IFN- assay with VV- or LCMV-specific CD8 T cells, we
identified two VV-specific epitopes, e7r130 (STLNFNNL) and
a11r198 (AIVNYANL) (Fig. 1A). The IFN- responses to VV-
e7r130 ranged between 1% and 9.9% (mean  standard error
of the mean, 2.2%  0.5%; n 	 22) of all CD8 T cells six days
after VV infection, whereas the IFN- response to VV-a11r198
ranged between 0.1 and 0.75% (mean  standard error of the
mean, 0.23%  0.05%; n 	 17). Six days after VV infection,
the VV-e7r130 and VV-a11r198 IFN- responses accounted for
approximately 10% and 1% of the anti-CD3 response, respec-
tively. The VV-e7r130 and VV-a11r198 peptide-specific T-cell
responses accounted for approximately 20% and 2%, respec-
tively, of the total VV-specific response as determined by stim-
ulation with the MHC class I-matched VV-infected MC57G
cells. In vivo CTL assays using peptide-pulsed splenocytes from
C57BL/6 mice as targets showed about 90% specific killing
(mean, 87%; range, 83 to 92%; n 	 6) for VV-e7r130 and 19%
(range, 15 to 23%; n 	 3) for VV-a11r198 (Fig. 1B). In vitro
51Cr release assays on syngeneic target cells (RMA-S) coated
with peptides, although not as sensitive, showed a similar
hierarchy (data not shown). These two newly identified VV
epitopes were also found to have the same relative binding
affinity for H-2Kb as LCMV-NP205, the epitope used to identify
them (Fig. 1C). We consider VV-e7r130 an immunodominant
H-2Kb-restricted epitope for VV, while VV-a11r198 is a sub-
dominant epitope in primary VV infection.
When these peptides were tested in IFN- or CTL assays
with splenocytes from mice infected with only LCMV 9 days
earlier, VV-a11r198 induced significant IFN- production in up
to 1% of all CD8 T cells (mean, 0.8%; range, 0.4 to 1%; n 	
5) and in vivo killing was more than 80% (86%; range, 78 to
94%; n 	 6), whereas VV-e7r130 failed to stimulate CD8 T
cells to produce IFN- or demonstrate cytotoxic activity (Fig.
1A and B). Although VV-e7r130 was identified by its potential
to be cross-reactive with LCMV, cells from LCMV-infected
mice did not appear to recognize this epitope.
Newly identified VV CD8 T-cell epitopes e7r130 and a11r198
are maintained in the T-cell memory pool. To analyze if the
VV epitope-specific immune response could be maintained in
the CD8 T-cell memory pool, we analyzed VV-infected
C57BL/6 mice during the acute phase of infection and more
than six weeks after infection. VV-e7r130 and VV-a11r198 re-
sponses in the spleen peaked at 6 days after VV infection as
measured by IFN- production upon in vitro peptide stimula-
tion (for e7r, a mean standard deviation of 2.2% 0.5% and
a range of 1 to 9.9% [n 	 22]; for a11r, a mean  standard
deviation of 0.23%  0.05% and a range of 0.1% to 0.75%
[n 	 17]) (Fig. 1 and 2A and B). CD8 T-cell responses specific
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to either epitope gradually declined over the first 30 days after
VV infection and stabilized thereafter, as demonstrated by
little change in their total number or frequencies between day
30 and 200 postinfection (Fig. 2A and B). Memory CD8 T cells
specific for VV-e7r130 frequencies were stable at 0.4% 
0.04% (range, 0.2 to 0.6% [n 	 11]) and for VV-a11r198 at
0.05%  0.02% (range, 0.01 to 0.1% [n 	 8]) for more than
200 days postinfection (Fig. 2A and B). The responses against
the VV epitopes were also detectable in peripheral sites, such
as the peritoneal cavity, the initial site of virus entry, at slightly
higher frequencies than in the spleen (Fig. 2A, row ii). Tet-
ramer staining with H-2Kb-containing VV-e7r130 allowed di-
rect visualization of antigen specific CD8 T cells without in
vitro stimulation and showed results similar to those deter-
mined by intracellular cytokine assays (Fig. 2A, row iii).
Analyzing intracellular cytokine production for both IFN-
and TNF- during the acute and memory phases of VV infec-
tion demonstrated that VV-specific CD8 T cells could produce
both cytokines in response to VV-e7r130 and VV-a11r198. The
determined ratio ([IFN-  TNF-]/[IFN-  TNF-])
was 0.5 at the peak of the VV-specific CD8 T-cell response
(day 6) and greater than 2 after 15 days after VV infection.
This is consistent with the previously demonstrated concept
that mature memory CD8 T cells are capable of producing
both cytokines (Fig. 2A, row iv) (48).
Immunodominant VV-e7r130-specific CD8 T cells elicit ef-
fector function during the acute phase of VV infection. During
the acute phase of VV infection, VV-e7r130-specific CD8 T-cell
cytotoxic activity paralleled cytokine production. In vivo killing
of VV-e7r130-labeled targets was 87% (range, 83 to 92%; n 	
6) 6 days after VV infection and declined to 34% (range, 10 to
46%; n 	 5) and 18% (range, 16 to 22%; n 	 5) 8 and 15 days,
FIG. 1. VV- or LCMV-specific CD8 T cells recognize the subdominant VV-a11r198 epitope, while only VV-specific CD8 T cells recognize the
dominant VV-e7r130 epitope. (A) Intracellular IFN- assay. Splenocytes from naı¨ve or day 6 VV- or day 8 LCMV-infected C57BL/6 mice were
stimulated as indicated in an ICS assay. The percentage of CD8 T cells producing IFN- is recorded in the upper left quadrant (gated on CD8
cells). Data are representative of five experiments (two to six mice/group). No stim, no stimulation. (B) In vivo cytotoxicity assay. CTL activity was
analyzed in naı¨ve or day 6 VV- or day 8 LCMV-infected C57BL/6 mice using CFSE-labeled targets coated with LCMV-NP205 (a), VV-a11r198 (b),
VV-e7r130 (c), or control ovalbumin SIINFEKL (d) peptide. Data are representative of two experiments (three to five mice/group). (C) RMA-S
stabilization assay. The newly identified VV epitopes stabilize H-2Kb on RMA-S cells in a standard stabilization assay. The mean fluorescence
intensities (MFI) of the H-2Kb expression to different concentrations of the indicated peptides are shown. Data are representative of two similar
experiments.
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respectively, after VV infection (Fig. 2C). Staining for total
CD8 T-cell granzyme B was consistent with these results (Fig.
2C). Interestingly, VV-e7r130-specific in vitro killing measured
by 51Cr release assay was more than fourfold lower than in vivo
killing (19% versus 87%) 6 days after VV infection, indicating
a much higher sensitivity for the in vivo killing assay. The
kinetics of VV-specific CD8 effector functions coincided with a
decrease of VV titers measured in several organs. VV titers
peaked at day 3 after infection and were significantly reduced
6 days postinfection. VV was cleared in the spleen and liver by
day 8 postinfection but persisted slightly longer in fat pads
and testes, clearing by 15 days postinfection (Fig. 2D). VV
PFU could not be detected in any organ (testis, fat pads,
spleen, liver, lung, brain, or salivary gland) 30 days postin-
fection, suggesting that the virus had been completely
cleared from the host.
VV-specific CD8 T-cell lines generated from VV-immune
mice respond to VV in vitro and in vivo. We next established
VV-e7r- and -a11r-specific T-cell lines by stimulating spleno-
cytes from VV-immune mice with the VV-specific peptides for
20 to 25 days in the presence of the IL-2. In 51Cr release
cytotoxicity assays, both lines were able to lyse VV-infected
FIG. 2. Maintenance of VV-epitope-specific CD8 T-cell responses into memory and VV clearance. (A) VV-e7r-specific CD8 T-cell response
measured by intracellular IFN- staining in the spleen (i) and in the PECs (ii) at various times after VV infection. (iii) Direct visualization of
VV-e7r-specific CD8 T-cell response by tetramer staining. Cells were gated on CD8. (iv) Increase in ratio of TNF--to-IFN- production
of VV-specific CD8 T cells in the spleen during VV infection. An ICS assay (gated on CD8CD44 T cells) indicated an increase in the ratio
of TNF- to IFN- ([IFN-  TNF-]/[IFN-  TNF-]) production from VV-e7r-specific CD8 T cells. Similar results were observed for
a11r-specific responses (data not shown). Data are representative of three experiments. (B) Kinetics of VV epitope-specific CD8 T-cell responses.
Splenic VV epitope-specific CD8 T-cell responses were analyzed by either tetramer staining or ICS (three to five mice/group). The total number
of antigen-specific cells (given plus or minus the standard error of the mean) equals the frequency of peptide-reactive cells multiplied by the total
number of CD8 cells. Data are representative of three experiments. (C) Effector functions of VV-specific CD8 T cells visualized by VV-e7r-specific
in vivo killing (■) and by intracellular granzyme B staining of total CD8 T cells ( ) 3 to 15 days after VV infection. (D) VV clearance. Organs
were harvested at the times indicated and plaque assays were performed (five mice/time point). VV could not be detected in any organ including
lung, kidneys, heart, brain, and salivary gland day 30 postinfection.
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targets (Fig. 3A). In vitro ICS assays also demonstrated that
the VV-e7r-specific and -a11r-specific lines produce IFN- and
TNF- in response to VV-infected MC57G cells (Fig. 3B).
However, stimulating with VV-infected MC57G cells in an ICS
assay was not as sensitive a technique as peptide stimulation or
the in vitro cytotoxicity 51Cr release assay using VV-infected or
peptide-coated targets. Both CFSE-labeled VV epitope-spe-
cific cell lines upon adoptive transfer proliferated in vivo in the
recipient mice upon VV infection, whereas control influenza A
virus NP366-specific lines did not (Fig. 3C). These results dem-
onstrate that these epitopes were processed and presented
during VV infection.
VV-e7r130-specific CD8 T cells reduce VV load. To investi-
gate a potential protective capacity of CD8 T-cell responses
against VV infection, we used two different methods, either
adoptive transfer of VV-e7r-specific CD8 T cells into the peri-
toneal cavity or immunization with ubiquitinated minigenes
expressing VV-e7r130. To directly test if VV-specific CD8 T-
cell responses could protect against VV infection, rested VV-
e7r130-specific CD8 T-cell lines were adoptively transferred i.p.
into recipient syngeneic naı¨ve mice, which were then infected
with VV. Control mice were injected with influenza virus
NP366-specific CD8 T-cell lines, which were documented not to
be cross-reactive with VV. Tetramer or ICS assays demon-
strated that more than 95% of each CD8 T-cell line was spe-
cific for the peptide used to generate the line (Fig. 4A). Three
days after adoptive transfer, the CFSE-labeled VV-e7r-specific
CD8 T cells had gone through three to six rounds of division in
response to the VV infection, while the influenza virus NP366-
specific cells did not proliferate (Fig. 4B). There was a signif-
icant 99% reduction in VV titers 3 days after VV infection in
the fat pads of the mice injected with the VV-e7r-specific line
compared to the titers in the mice injected with the control
influenza virus NP366-specific line (Fig. 4C). Similar results
were observed in a second experiment, in which a PBS injec-
tion was compared to injection with the VV-e7r130 cell line
(Fig. 4C). Our VV dose was not lethal, but control mice ap-
peared to be more ill, as demonstrated by significantly greater
weight loss (Fig. 4D), ruffled fur, shivering, and a decrease in
FIG. 3. VV-e7r-specific and VV-a11r-specific lines generated from
VV-immune mice respond to VV in vitro and in vivo. (A) In vitro 5-h
51Cr release cytotoxicity assays demonstrate specific lysis of peptide-
coated RMA-S cells and VV-infected MC57G cells. Control targets
included RMA-S cells, MC57G cells, and LCMV-infected MC57G
cells. (B) In vitro ICS assays show that the e7r-specific and a11r-
specific lines produce IFN- and TNF- in response to VV-infected
MC57G cells. As a control, these lines did not produce cytokines to
LCMV-NP396 (data not shown). (C) Both VV-e7r-specific and VV-
a11r-specific lines proliferated in response to VV in vivo. VV-e7r-
specific CD8 T-cell line (VV-p10-3, generated from a VV-immune
mouse) and a11r-specific CD8 T-cell line (L/P24-7, generated from an
LCMV- and VV-immune mouse) proliferated in response to VV in-
fection i.p. as assessed by loss of CFSE by day 4 after adoptive transfer
of the cell line i.p. into syngeneic C57BL/6 mice. The PECs collected
from these mice were used in an ICS assay and produced IFN- only
to the VV peptide used originally to stimulate the line and did not
respond to the alternate VV peptide or the control influenza virus
NP366 peptide. The control NP366-specific line generated from an in-
fluenza virus-immune mouse did not proliferate in response to VV and
did not produce IFN- in response to stimulation with VV peptides.
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activity, than the mice treated by immunization with the VV-
specific T-cell lines.
A second method utilized three intramuscular immuniza-
tions every 14 days with an ubiquitinated DNA minigene spe-
cific for the VV-e7r130 sequence to demonstrate the protective
role of CD8 T-cell responses. The VV-e7r130-specific CD8
T-cell responses measured by intracellular IFN- (Fig. 5A and
B) and in vitro cytotoxicity (Fig. 5C) assays were increased
approximately three- to sixfold compared to nonimmunized
mice or mice immunized with the F3Ub vector only. Six days
after VV infection, the VV-e7r130-specific CD8 T-cell popula-
tion was significantly higher, at 2.4  106 total cells (range,
1.0 106 to 5.1 106; n	 5; P	 0.04, versus the F3Ub group)
in VV-e7r130-immunized mice, than the T-cell populations in
F3Ub-immunized mice, at 4  105 cells (1  105 to 7  105;
n 	 5), and nonimmunized control mice, at 7  105 cells (4 
105 to 13  105; n 	 5) (Fig. 5A and B). Also, the specific lysis
of VV-e7r130-labeled targets in VV-e7r130-immunized mice
was higher than those in nonimmunized and F3Ub-immunized
control mice (Fig. 5C). Analyzing VV titer in fat pads by
plaque assays, we documented a significant 90% reduction of
virus titer 6 days after VV infection in VV-e7r130-immunized
mice compared to that of the group immunized with the vector
only (Fig. 5D).
In a second experiment, we also observed a 90% reduction
in VV titers (Fig. 5D), as well as significantly decreased weight
loss (Fig. 5E) from VV-e7r minigene immunization compared
with that from control LCMV-NP396 minigene immunization.
DISCUSSION
Through the study of T-cell cross-reactivity between two
heterologous viruses, we found that sequence similarity to a
known epitope may be a useful tool to help predict immuno-
genic epitopes to large viruses, such as VV. This led to the
finding that VV infection induced potent CD8 T-cell responses
that were well maintained into memory and that VV-specific
CD8 T cells could play a significant role in mediating protec-
tive immunity to VV. Our initial observations of VV-induced
proliferation of T cells specific to an LCMV epitope, NP205, in
LCMV-immune mice indicated that this LCMV epitope-spe-
cific response potentially included cross-reactive T cells that
could also recognize VV (8, 26, 27). Mechanisms for CD8
T-cell cross-reactivity can be manifold. Molecular mimicry, in
which a different peptide retains sites that are necessary for
interaction with the TCR, is one of several paths to cross-
reactive T-cell responses (43), as in the case with the NP205
epitopes of LCMV and PV (5). It had been difficult to identify
VV-specific MHC-I-restricted epitopes, as VV encodes more
than 200 proteins and theoretically thousands of potential
epitopes (21). Basing our method on the concept of molecular
mimicry, we scanned the VV genome for sequence similarities
to LCMV-NP205 and identified two VV immunogenic epitopes
after screening only 115 peptides. This would suggest that this
technique adds another approach to identifying immunogenic
epitopes and could complement more conventional methods
using algorithms based on MHC binding motifs (H. G. Ram-
mensee, J. Bachmann, and S. Stevanovic, SYFPEITHI, a data-
base of MHC ligands and peptide motifs—epitope prediction
[http://www.syfpeithi.de/Scripts/MHCServer.dll/EpitopePrediction
.htm]). Paradoxically, we identified an immunodominant VV
epitope, VV-e7r130, that did not generate cross-reactive T-cell
responses with LCMV and a subdominant epitope, VV-
a11r198, which did generate cross-reactive T-cell responses with
LCMV. Further characterization of these responses in subse-
quent studies has confirmed these observations (Cornberg et
al., submitted). Identification of these VV-specific epitopes led
to a better understanding of the role CD8 T cells play during
VV infection. This strategy may be useful for identifying new
CD8 T-cell epitopes for large viruses such as VV. This tech-
nique is particularly useful for identifying epitopes that may be
missed by the more conventional methods, such as VV-a11r198.
VV-a11r198 was not identified in a recent report using algo-
rithms to identify VV epitopes in C57BL/6 mice (35). Al-
though the VV-a11r198 epitope is a weak epitope in naı¨ve
C57BL/6 mice infected with VV because of its ability to acti-
vate cross-reactive LCMV-specific memory CD8 T cells, its
frequency can be significantly increased in some LCMV-im-
mune mice infected with VV based on the private specificity of
the memory T-cell repertoire of each mouse (27).
Both epitopes VV-e7r130 (STLNFNNL) and VV-a11r198 (A
IVNYANL) were conserved among vaccinia virus strains (WR,
FIG. 4. VV-e7r-specific CD8 T cells reduce VV titers in vivo.
(A) VV-e7r-specific (VV-e7r130) or influenza virus NP366-specific (IV-
NP366) CD8 T-cell lines generated from VV-immune or influenza
virus-immune mice, respectively, demonstrated antigen specificity in
an ICS assay (representative of two similar experiments). (B) The
VV-e7r-specific CD8 T-cell line, but not the IV-NP366-specific cell line,
proliferated in response to VV infection (i.p.), as assessed by loss of
CFSE day 3 after adoptive transfer (i.p.) of the cell line into syngeneic
C57BL/6 mice. (C) Significant reduction in VV titers in two experi-
ments on days 3 and 4 after VV infection in mice injected with the
VV-e7r-specific (black circles) or control influenza virus NP366-specific
(gray circles) (experiment 1) cell line or PBS (white circles; experiment
2) (# and *, P 
 0.05; four or five mice/group). (D) Significant
protection from weight loss day 4 after VV infection in mice injected
with VV-e7r-specific cell line compared to protection from weight loss
in mice given PBS (P
 0.003; five mice/group). Weight is expressed as
a percentage of the original weight prior to infection.
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FIG. 5. VV-e7r-expressing ubiquitinated DNA minigene vaccine increased e7r-specific CD8 T cells and reduced VV load. Increased frequency
(A) and total number (B) of the VV-e7r130 epitope-specific CD8 T cells day 6 after VV infection in mice immunized three times intramuscularly
with e7r-expressing ubiquitinated DNA minigene as assessed by ICS assay. Data are from one representative mouse (five mice/group). The total
number of VV-e7r-specific cells equals the frequency of antigen specific cells multiplied by the total number of viable cells. There was a greater
number of VV-e7r130 epitope-specific cells in the VV-e7r130 minigene-immunized mice than in mice given either control, minigene vector or PBS
(P values of
0.05 and
0.08, respectively; n	 5). Data are representative of two experiments. No stim, no stimulation. (C) Enhanced cytotoxicity
as measured by 51Cr release assays on splenocytes from the VV-e7r130 minigene-immunized mice compared to controls given minigene vector or
PBS. Targets included peptide-coated RMA-S cells or VV-infected MC57G cells (five mice/group). (D and E) Significant reduction in VV titers
day 6 after VV infection in mice injected with VV-e7r-specific minigenes (■) compared to control-vector-immunized mice (■) (log PFU/ml, 2.6 
0.4 versus 3.7 0.2; P
 0.05; seven and five mice, respectively) or control LCMV-NP396-specific minigene-immunized mice (x) (log PFU/ml, 2.7 
0.4 versus 3.7  0.2; P 
 0.07; eight and five mice, respectively). (E) Significant protection from weight loss during VV infection of VV-e7r130-
mingene immunized mice (●) compared to control LCMV-NP396 minigene-immunized mice (E) (P 
 0.0004; eight and five mice, respectively;
paired Student’s t test). Weight is expressed as a percentage of the original weight prior to infection.
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Ankara, and Copenhagen), other poxviruses (cowpox, mon-
keypox, camelpox, and ectromelia virus), and also variola virus.
VV-e7r is a soluble myristylated late protein of unknown func-
tion, and it is not associated with the virus membrane (30). The
36- to 40-kDa putative VV protein a11r is one of the 49 gene
products that are conserved in all sequenced poxviruses (54)
and was found to be associated with the putative DNA-pack-
aging protein A32L required for virion morphogenesis (34).
Recently, Resch et al. showed that the a11r protein is also a
late protein that seems to be required to form normal virion
membranes (40).
Although VV-specific CTLs were first described in 1975
(29), the importance of CD8 T cells in poxvirus infections still
remains somewhat controversial and remains an important
question, since newer vaccines are being designed to include
induction of CD8 T-cell responses. Earlier studies had mixed
results. Studies with ectromelia virus (mouse pox), a poxvirus
closely related to VV, in mice demonstrate a consistent and
absolute role for CD8 T cells in the control of primary infec-
tion, although antibody responses have been found to be im-
portant later in infection (4, 6, 15, 25). Tscharke et al. have
demonstrated that immunization with a newly identified im-
munodominant peptide provided significant protection
against a secondary lethal ectromelia infection, suggesting
that CD8 memory T-cell responses could contribute to pro-
tective immunity to ectromelia virus (53). However, studies
with VV in mice have been less definitive in identifying a
role for CD8 T cells in both primary and secondary infec-
tions (3, 13, 49, 50, 59).
Studies examining the role of CD8 T cells during primary
infection with VV have suggested that CD8 T cells may not be
essential but they do play a supportive role. In one study using
high-dose VV, 2-microglobulin knockout mice (2 m/
mice) which lack CD8 T cells were able to recover from VV
infection, suggesting that CD8 T-cell responses were not es-
sential during the primary infection, but this study did not rule
out that they could play a significant role. Recovery was de-
scribed as the disappearance of skin lesions and weight gain
after intradermal inoculation, and VV titers were not analyzed
(50). In another study, Belyakov et al. (3) showed that CD8 T
cells alone in the absence of an antibody response were not
sufficient to protect against VV infection during a primary
infection (analyzed by weight differences). However, the de-
pletion of CD8 T cells in the absence of an antibody response
prevented late recovery, suggesting that CD8 T cells could
make the difference between survival and death (3). A recent
study by Xu et al. also showed that CD8 T cells can contribute
to protection against VV, but CD4 T cells and antibodies may
play a more important role, at least in primary infection (59).
There are less data available for the role of CD8 T cells
during secondary VV infection. One study by Snyder et al. (49)
documented protection against lethal secondary VV challenge
in HLA-A2 transgenic mice by vaccination with an MHC-I-
restricted T-cell epitope, suggesting that CD8 memory T-cell
responses were important in protection against VV. These
mice received the VV peptide three times subcutaneously ac-
companied with 50 nmol of a hepatitis B virus core helper
peptide, 5 g of granulocyte-macrophage colony-stimulating
factor (GM-CSF), 800 IU of IL-2, and incomplete Freund’s
adjuvant. However, these mice with only a single CD8 epitope-
specific memory response did not have complete protection, as
some mice lost weight and some mice died. This did not occur
in mice previously immunized with the whole virus (49). An-
other study by Daftarain et al. (12) using HLA-A2 transgenic
mice to identify human immunodeficiency virus (HIV)-specific
CD8 T-cell epitopes, demonstrated that immunization with a
Th-CTL fusion peptide against an HIV epitope led to en-
hanced clearance of recombinant VV expressing the HIV
epitope but was highly dependent on coadministration of pep-
tide with cytosine-phosphate-guanine DNA (12). However, in
another study by Drexler et al., immunization with HLA-A2-
restricted VV-specific CD8 peptide vaccines was not able to
protect HLA-A2 transgenic mice against a secondary infection
with WR VV infection (13). Interestingly, research into se-
quential heterologous virus infections, in which there are no
cross-protective neutralizing antibodies, shows that cross-reac-
tive LCMV-specific memory CD8 T cells mediate protective
immunity early in VV infection, suggesting that CD8 T cells
could play an important role upon secondary VV challenge (8,
46; Cornberg et al., submitted). Our studies would strongly
support the contention that CD8 memory T cells could play an
important role in protection against VV during secondary in-
fections. VV-e7r130-specific ubiquitinated DNA immunization
significantly enhanced epitope-specific CD8 memory T-cell re-
sponses in vivo and resulted in a 90% reduction of VV titers on
secondary challenge. Another technique allowed a more direct
test of the ability of effector type memory CD8 T cells to
protect against VV in a peripheral site. Epitope-specific CD8 T
cells were activated in vitro and then rested into a quiescent
state before transfer into the intraperitoneal cavity prior to
challenge with VV. Only 106 cells were required to reduce VV
titers more than 95%. These data demonstrate a number of
points. First, e7r130-specific CD8 T cells recognized VV-in-
fected targets in vivo, supporting the concept that this epitope
is processed and presented. Second, CD8 T cells provided
protection against VV, especially when delivered at the site of
the infection. This underlines the concept that peripheral ef-
fector memory T cells can contribute to the early clearance of
a virus infection by their immediate response (8, 24, 31) and
justifies the use of vaccines which induce CD8 T-cell-depen-
dent immunity. Finally, T cells can encounter their antigen
presented on APCs in the periphery at the site of the infection.
It also suggests that adoptive transfer of in vitro generated
antigen-specific CD8 T cells could be a potential therapeutic
intervention against poxviruses as has been shown for other
infectious diseases (41). This model using intraperitoneal in-
jection of CD8 T cells also provides a useful tool to study the
effect of in vitro generated CD8 T cells upon VV-infected mice
or in other viral infection models. To our knowledge, this is the
first report of immunization with an ubiquitinated minigene
expressing a VV-specific CD8 epitope or with the direct trans-
fer of a VV-specific CD8 T-cell line leading to protective
immunity without added CD4 helper peptides or adjuvants,
and this clearly demonstrates that memory CD8 T cells can
mediate protection against VV.
These studies are an excellent baseline for a better under-
standing about VV-specific memory CD8 T-cell responses in
the context of other heterologous virus infections. For in-
stance, the VV epitope-specific CD8 T cells were maintained
in the memory population with the same immune hierarchy
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even more than 200 days after VV challenge (Fig. 2A and B).
However, this analysis is not comparable with the human sce-
nario in which one is exposed to numerous antigens during a
lifetime. Encountering new infections induces immune re-
sponses to the new pathogen and results in attrition of non-
cross-reactive memory T cells specific to the previous antigen
(44). Studies in humans have shown that there is a 10-fold
decrease in VV-specific memory over a lifetime (22). Consid-
ering the number of infections which humans can encounter,
this appears to be a minimal loss. However, when memory
CD8 T cells are able to generate cross-reactive responses to
new antigen, their high frequency and activation state give
them an advantage over naı¨ve T cells and can lead to a pref-
erential expansion of the cross-reactive CD8 T cells, which can
alter the hierarchy of T-cell responses (5, 11). It is possible that
cross-reactive VV-specific T cells could preserve VV-specific
memory and can explain the maintenance of VV-specific im-
mune responses more than 40 years after smallpox vaccination
with VV (22). It is possible that cross-reactive memory re-
sponses, which may be of lower avidity to the new heterologous
virus, are not always as efficient at clearing the new pathogen
as higher-avidity de novo non-cross-reactive responses. These
lower-avidity responses to VV may be more prone to stimu-
lating immunopathology especially if these responses are di-
rected at late antigens like VV-a11r. Having these systems now
in place, we are better able to address the role heterologous
immunity and cross-reactivity play in mediating protective im-
munity and/or immunopathology during VV infection a model
for smallpox vaccination.
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